Blog
RSS FeedPosted by Michael Wonder on 18 Feb 2021
Ultragenyx announces approval of Dojolvi (UX007/triheptanoin) in Canada for the treatment of long-chain fatty acid oxidation disorders in adults and children
17 February 2021 - First approved treatment for adult and paediatric patients with long-chain fatty acid oxidation disorders in Canada. ...
Posted by Michael Wonder on 29 Dec 2020
Vertex announces new drug submission for investigational triple combination medicine for the treatment of cystic fibrosis has been accepted for priority review by Health Canada
28 December 2020 - Vertex Pharmaceuticals Incorporated today announced its New Drug Submission for Trikafta, Vertex’s investigational triple combination medicine, ...
Posted by Michael Wonder on 12 Nov 2020
Cystic Fibrosis Canada says 'life-changing' drug coming to Canada, but approval months away
11 November 2020 - The drug's manufacturer says it's moving forward with its cystic fibrosis medicines in Canada. ...
Posted by Michael Wonder on 10 Nov 2020
Health Canada approves Maviret 8 week treatment duration for treatment naïve patients with genotype 3 compensated cirrhosis
10 November 2020 - Maviret (glecaprevir/pibrentasvir) is the only 8 week oral treatment approved for all hepatitis C virus genotypes. ...
Posted by Michael Wonder on 22 Sep 2020
Knight and TherapeuticsMD announce Health Canada approval of Bijuva
21 September 2020 - Knight Therapeutics and TherapeuticsMD announced today the approval of Bijuva (estradiol and progesterone) capsules by Health ...
Posted by Michael Wonder on 12 Jun 2020
Health Canada issues notice of compliance for Bausch Health's Duobrii
11 June 2020 - Topical combination improving the sings and symptoms of plaque psoriasis in adult patients with moderate to ...
Posted by Michael Wonder on 21 May 2020
Mithra and Searchlight Pharma announce filing of new drug submission for Estelle in Canada
20 May 2020 - Searchlight Pharma's new drug submission for a novel combined oral contraceptive accepted for review by Health Canada. ...
Posted by Michael Wonder on 13 Apr 2020
Gilead Canada submits supplemental new drug submission to Health Canada for Descovy for HIV pre-exposure prophylaxis
9 April 2020 - Submission supported by data from the DISCOVER trial, which evaluated the safety and efficacy of Descovy compared ...
Posted by Michael Wonder on 21 Mar 2020
Janssen announces Health Canada approval of Cabenuva, the first long-acting regimen for the treatment of HIV
20 March 2020 - Cabenuva offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression. ...
Posted by Michael Wonder on 28 Feb 2020
Nuvo Pharmaceuticals announces Health Canada approves Suvexx for the acute treatment of migraine
27 February 2020 - Canadian launch anticipated in the second half of 2020. ...
Posted by Michael Wonder on 04 Dec 2019
Health Canada grants priority review status for Heron Therapeutics' new drug submission for HTX-011 for management of post-operative pain
3 December 2019 - Heron Therapeutics today announced that Heron's new drug submission for HTX-011 for the management of postoperative pain ...
Posted by Michael Wonder on 22 Nov 2019
Health Canada approves Lonsurf (trifluridine/tipiracil) for adults with metastatic gastric cancer during stomach cancer awareness month
21 November 2019 - New indication improves overall survival for end stage metastatic disease ...
Posted by Michael Wonder on 24 Oct 2019
Knight Therapeutics and SIFI announce approval of Netildex in Canada
23 October 2019 - Knight Therapeutics and SIFI today announced that Health Canada has approved Netildex for the treatment of inflammatory ...
Posted by Michael Wonder on 14 Dec 2018
Health Canada grants market authorisation for Orkambi (lumacaftor/ivacaftor) for children with cystic fibrosis aged 2 to 5 years old with most common form of the disease
13 December 2018 - Orkambi is the first medicine in Canada to treat the underlying cause of cystic fibrosis in young ...
Posted by Michael Wonder on 13 Jul 2018
Gilead receives approval in Canada for Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for the treatment of HIV-1 infection
12 July 2018 - Gilead Sciences Canada today announced that Health Canada has granted a notice of compliance for Biktarvy (bictegravir ...